Personalized medicine is the customization of medical treatment to a person’s unique molecular and genetic characteristics. Research in this field is increasing our ability to predict which medical treatments will be safe and effective for each patient, improves our ability to diagnose and treat disease, and offers the potential for earlier disease detection.

Dr. Gualberto Ruaño, MD, PhD, is a pioneer in the field of personalized medicine and the inventor of molecular diagnostic systems used worldwide. Dr. Ruaño's clinical research interests include the development of novel DNA diagnostic products for personalized clinical management of cholesterol lowering medications and the identification of DNA markers relevant to schizophrenia, both Phase II projects funded by the NIH. Dr. Ruaño, President and CEO of Genomas Inc., and his colleagues at Hartford Hospital are bringing DNA-Guided Medicine to Healthcare Today.